Research Program Exclusivity Sample Clauses
The Research Program Exclusivity clause establishes that the parties involved agree to conduct research activities exclusively with each other within a defined field or subject area. In practice, this means that neither party may collaborate with third parties or independently pursue similar research projects that fall within the scope of the agreement during the exclusivity period. This clause is designed to protect the interests and investments of both parties by preventing competition and ensuring that the results of the research program remain unique to their collaboration.
Research Program Exclusivity. 3.1.1 Receptos represents and warrants that as of the Effective Date, Receptos is not a party to an agreement with any Third Party regarding structure-based Drug Discovery directed to Target, and Receptos covenants that it will not during the Term directly or through an Affiliate that it controls, enter into an agreement with any Third Party regarding structure-based Drug Discovery directed to Target. During the Term, Receptos shall not disclose any Lilly Research Program Know How or Joint Research Program Know How to any Third Party or use any such Research Program Know How in support of any collaboration with a Third Party directed to Target.
3.1.2 Lilly represents and warrants that as of the Effective Date, Lilly is not a party directly or through an Affiliate to any agreement with any Third Party regarding *** directed to Target, and Lilly covenants that it will not during the Term directly or through an Affiliate, enter into an agreement with any Third Party regarding *** directed to Target; provided, however, that this Section 3.1.2 shall not prohibit Lilly or its Affiliates from entering into or persisting in any Contract Research Arrangement with a CRE. During the Term Lilly shall not disclose any Receptos Research Program Know How or Joint Research Program Know How to any Third Party or use any such Research Program Know How in support of any collaboration with a Third Party directed to Target.
3.1.3 For the avoidance of doubt, nothing in this Agreement is intended to, nor does any term of this Agreement (i) prevent or limit in any way the right of Lilly to pursue independently (i.e., not in collaboration with any Third Party) any research and development activities (including without limitation those related to Target and to structure *** Confidential material redacted and filed separately with the Commission. based research and Drug Discovery and development activities related to Target or otherwise) and to pursue nonstructural based Hit identification activities, such as biochemical and cell-based screening; (ii) require Lilly to contribute as Research Program Know How any research or development results or information for the purposes of this Agreement or the Research Program; or (iii) deprive Receptos of the right to exercise its discretion in the governance of the Research Program as it relates to the transfer of any proprietary Receptos information or materials which are elements of enabling technology for Protein Expression, Crystallizatio...
Research Program Exclusivity. During the Research Term, each Party shall conduct all of its research efforts in the Field and; pursuant to the Research Program and the terms and conditions set forth in this Agreement; and [ * ] * Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
Research Program Exclusivity. On a Research Program-by-Research Program basis, commencing on the Research Target Combination License Date for a given Licensed Research Target Combination that is the subject of a Research Program and ending upon the earlier of (i) the five (5) year anniversary of the Initiation of a Phase 1 Clinical Trial for the first Research Product for such Research Program or (ii) the termination of such Research Program in accordance with Section 5.10 (Research Program Termination) or Article 18 (Term and Termination), except as permitted under this Agreement, including in connection with the conduct of MacroGenics’ activities with respect to such Research Program during the Research Term pursuant to the applicable Research Plan, MacroGenics shall not, itself, or with or through any of its Affiliates or any Third Party, Develop, have Developed, Commercialize, or have Commercialized any compound or product that is directed to the Licensed Research Target Combination that is the subject of such Research Program.
Research Program Exclusivity. During the Term of the Research Program, Sequana will not conduct, alone or with any Third Party any research activities in which genetics and genomics technologies are used specifically to discover Genes responsible for Schizophrenia or Bipolar Disorder, except as permitted pursuant to Section 2.3. It is understood and agreed that, subject to Section 4.9, either Party may conduct research and commercialization activities with respect to (i) pharmacogenetics whether or not related to Schizophrenia or Bipolar Disorder, (ii) determining the function of Genes identified by Third Parties whether or not related to Schizophrenia or Bipolar Disorder and in no event will Sequana utilize Collaboration Technology in such research effort and further that Sequana shall cease such research with such Third Party in the event that the function of such Gene(s) is determined to be related to Schizophrenia or Bipolar Disorder. or (iii) diseases other than Schizophrenia or Bipolar Disorder, alone or with third parties.